Celliant as an Advanced Technology: A Conversation with Dr. Coyle

This is the second post in a three-part series of conversations with Dr. Michael Coyle, the Chief Science Officer at Celliant. Dr. Coyle is also an Adjunct Assistant Professor in Human Performance at the University of Indiana-Bloomington and an expert in cardiopulmonary physiology. Read Part One.

As an emerging technology company, our prospective clients and customers often pose the bottom-line question: does this stuff really work?  The answer is simple: yes. And we know it works because we prove it through clinical studies.

The way it works, in the words of our Chief Science Officer, Dr. Michael Coyle, is as follows: “Celliant is a technology that enhances a process that already occurs in the body; delivering blood flow to exercising muscles already occurs. We have a technology and a product that takes naturally occurring infrared light and returns it back to the tissue and to the skin and into the capillary to increase blood flow to further deliver more oxygen and blood to the working muscle and tissue—to give it more substrate, or energy, to do more work.

It isn’t easy being the purveyors of an advanced technology in a market that isn’t looking to be disrupted.   But we relish the chance to challenge the market and back up our claims through science.  In a recent article in Scientific American, Shawn Lawrence Otto, the author of Fool Me Twice: Fighting the Assault on Science in America, argues that “science constantly disrupts hierarchical power structures and vested interests in a long drive to give knowledge, and thus power, to the individual.”

Through shaking things up, we know that we’re opening ourselves to skepticism.  A healthy skepticism, however, is something we have no problem with.  Indeed, our own Dr. Coyle remembers a conversation with a colleague in which he realized the value of good questioning: “We were having a light-hearted conversation about the difference between the curmudgeon [someone who refuses to consider new technology] and the early adopter. My friend said, ‘Well I’m a skeptic. But just because I’m a skeptic doesn’t make me a non-believer.’”

It’s a state of mind that has been important to Dr. Coyle, and the rest of us here at Celliant.  “Inherently you have to be a skeptic,” Coyle notes.  “But what I think and what I’ve noticed is that you have to be very careful about crossing over that line between skepticism and cynicism. And on the other side of it is being so enthusiastic about your own work that you cross over into being a zealot. In my opinion, the good academic, the well-centered academic is the one who can be a constructive skeptic, so they can see the body of work for what it is, and see the strengths and the weaknesses.”

We at Celliant approach our work in this way: enthusiastically forging ahead as early adopters with new and innovative technology, but doing so with a tempered and measured skepticism, ensuring that our projects are proceeding in the most factual and scientifically rigorous way possible.  We welcome your comments and questions, and hope to engage in thoughtful debate, through which to keep moving forward.

– See more at: http://celliant.com/blog/celliant-blog/celliant-as-an-advanced-technology-a-conversation-with-dr-coyle/#sthash.zj9EnMxm.dpuf